VolitionRX

US: VNRX

Market Cap$116m

Last Close $2.02

VolitionRx is a clinical diagnostics company developing easy-to-use and cost-effective blood tests to diagnose a range of diseases in humans and animals including sepsis and cancer. Diagnostic Nu.Q tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid.

More VolitionRX content > View more
Register to receive research on VolitionRX as it is published
Share price graph
Price performance
%
1m
3m
12m
Actual (15.1) (18.2) (35.0)
Relative* (21.4) (22.3) (31.6)
52-week high/low US$4.1/US$1.9
*% relative to local index
Key management
Cameron Reynolds CEO
Terig Hughes CFO
Jake Micallef Chief Scientific Officer
Scott Powell Director of IR